Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496058 | 0.84 | ALOX15 (0.45) | ALDH1A1KMT2ASIGMAR1L3MBTL1MAPK1 | |
| SCHEMBL495858 | 0.84 | MAPK1 (0.44) | SMN1; SMN2ALDH1A1KMT2ATP53MAPT | |
| SCHEMBL591468 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL6171928 | 0.75 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL6941197 | 0.75 | MAPT (0.62) | SMN1; SMN2ALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL6581538 | 0.75 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL10129614 | 0.73 | NR2F2 (0.40) | ALDH1A1KMT2AMEN1MAPTSIGMAR1 | |
| SCHEMBL7997377 | 0.73 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL6576971 | 0.71 | SMN1; SMN2 (0.74) | SMN1; SMN2ALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL8004123 | 0.71 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1KMT2AMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | SMN1; SMN2 1960/4885ALDH1A1 1210/4885KMT2A 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.